We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Nulibry

News List

FDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A americanpharmaceuticalreview
March 05, 2021
The U.S. Food and Drug Administration (FDA) approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A, a rare, genetic, metabolic disorder that typically presents in the first few days of ...
FDA approves Nulibry to treat Molybdenum Cofactor Deficiency Type A pharmatimes
March 02, 2021
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma and Origin Biosciences’ Nulibry (fosdenopterin), making it the first treatment to be authorised to reduce the risk of mortality in patients with molybdenum cofactor deficiency ...